Sunandana Chandra, MD, MS, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, discusses data from a first in human study of ARV-110, an androgen receptor PROTAC degrader in patients with metastatic castrate-resistant prostate cancer following enzalutamide and/or abiraterone. The study showed an acceptable safety profile and clinical activity in these patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).